Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles O'keeffe Insider Profile
4 Followers
Charles O'keeffe, Director at Catalyst Pharma, holds 685.72K shares in Catalyst Pharma (Ticker: CPRX). Most recently, Charles O'keeffe Bought $60,000 shares of Catalyst Pharma on Jan 03, 2024 for an estimated value of 67.80K.
Profitable Transactions
14 out of 28 Profitable Transactions
Average Return
+20.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Charles O'keeffe's holdings
Insider Roles
Director
Roles that Charles O'keeffe holds in companies
Most Profitable Insider Trade
The most profitable trade made by Charles O'keeffe
Charles O'keeffe's Trading History
List of latest transactions for each holding click on a transaction to see Charles O'keeffe's performance on stock
You May Also Like
Charles O'keeffe insider profile FAQ
What is the percentage of profitable transactions made by Charles O'keeffe?
The percentage of profitable transactions made by Charles O'keeffe is 50%.
What is the average return per transaction made by Charles O'keeffe?
The average return per transaction made by Charles O'keeffe is 20.70%.
What stocks does Charles O'keeffe hold?
Charles O'keeffe holds: CPRX stocks.
What was Charles O'keeffe’s latest transaction?
Charles O'keeffe latest transaction was an Informative Buy of $67.80K.
What was Charles O'keeffe's most profitable transaction?
Charles O'keeffe’s most profitable transaction was an Informative Buy of CPRX stock on July 12, 2016. The return on the trade was 288.00%.
What is Charles O'keeffe's role in Catalyst Pharma?
Charles O'keeffe's role in Catalyst Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.